Author:
Voss Rachel K.,Massarweh Nader N.,Roland Christina L.
Funder
Cancer Prevention and Research Institute of Texas
Office of Research and Development
Publisher
Springer Science and Business Media LLC
Reference4 articles.
1. Dagher R, Cohen M, Williams G, et al. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res. 2002;8:3034–8.
2. FDA grants imatinib (Gleevec) full approval for adjuvant treatment of GIST. Oncology Williston Park. 2012;26(3):264, 309.
3. Voss RK, Massarweh NN, Chiang Y-J, Somaiah N, Feig BW, Roland CL. National utilization of imatinib in the management of resected gastrointestinal stromal tumors. Ann Surg Oncol. https://doi.org/10.1245/s10434-021-10141-8.
4. Klug LR, Corless CL, Heinrich MC. Inhibition of KIT tyrosine kinase activity: two decades after the first approval. J Clin Oncol. 2021;39(15):1674–86.